TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Windtree Therapeutics, Inc. (OTC: WINT) Investor Investigation Over Possible Wrongdoing Announced

  • Investors who purchased shares of Windtree Therapeutics, Inc. (OTC: WINT) and currently hold any of those OTC: WINT shares have certain options and should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

Company
Windtree Therapeutics, Inc.
Security
OTC: WINT

Summary

An investigation on behalf of current long-term investors in shares of Windtree Therapeutics, Inc. (OTC: WINT) was announced over potential breaches of fiduciary duties by certain officers and directors at Windtree Therapeutics.

The investigation by a law firm concerns whether certain Windtree Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.

Warrington, PA based Windtree Therapeutics, Inc., a biotechnology company, focuses on developing surfactant therapies for respiratory diseases and other potential applications. Windtree Therapeutics, Inc. reported that its annual Total Revenue declined from $2.04 million in 2016 to $1.48 million in 2017 and that its Net Loss declined from $39.49 million in 2016 to $18.44 million in 2017.

Shares of Windtree Therapeutics, Inc. (OTC: WINT) declined from $66.00 per share in October 2016 to as low as $2.53 per share in October 2018.

Start Monitoring Your Investments